Clinical TrialID 2588
Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging
NCT01898182
Cutaneous Photoaging
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 2588
- Evidence Id
- 2588
- Core Evidence Id
- 2588
- Source Clinical Trial Id
- 2567
- Herb2 Clinical Trial Id
- HBCT002567
- Nct Id
- NCT01898182
- Title
- Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging
- Status
- Completed
- Phase
- Phase 4
- Study Result
- No
- Study Condition
- Cutaneous Photoaging
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:
- Intervention
- OTHER: Kinetin, N6-furfuryladenine, 0.1%
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Gender
- Female
- Age
- Adult, Older_Adult
- Enrollment
- 132
- Outcome Measure
- Skin Roughness, Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12, 12 weeks|Pigmentation, Also called Mottling or Blotchiness. This is measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12, 12 weeks|Fine wrinkles, Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12, 12 weeks|Global Improvement in Cutaneous Photoaging, Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12, 12 weeks|Pores, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Wrinkles, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Texture, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Porphyrins, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Visual Spots, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|UV spots, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Brown Spots, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks|Red Areas, Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8., 12 weeks
- Sponsor Collaborator
- Makati Medical Center|A. Menarini Philippines, Inc.
- Funded By
- OTHER
- Location
- Makati Medical Center, Makati City, Metro Manila, 1229, Philippines|Makati Medical Center Department of Dermatology, Makati City, NCR, 1229, Philippines
- Other Id
- MMCDeptofDerma-Kinerase-2013
- Start Date
- 2013-11
- Primary Completion Date
- 2014-07
- Completion Date
- 2014-09
- First Posted
- 2013-07-12
- Results First Posted
- Last Update Posted
- 2014-09-15
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT01898182
- Title Cn
- Title En
- Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging
- Bilingual Status
- semi_complete